Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982149 · ClinicalTrials.gov registry record
Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 27
- Enrollment target
NCT01982149 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 27 participants.
The verdict
NCT01982149 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
Lung cancer, largely the result of cigarette smoking, is the leading cause of cancer death in the United States, killing over 160,000 people in 2010, more than breast, colorectal, and prostate cancer combined. Since only 10% of heavy smokers develop lung cancer and 20% of lung cancers develop in nonsmokers, it is thought that genetic predisposition plays an important role. This study proposes to examine the genetic correlation between nasal and bronchial epithelium and to identify a patient's risk for lung cancer earlier.
Interventions
- GENETIC Group 1
- GENETIC Group 2
- GENETIC Group 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982149
The ClinicalTrials.gov registry entry for NCT01982149 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Group 1 is the first listed.
NCT01982149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982149 about?
NCT01982149 is a clinical study titled "Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer". Lung cancer, largely the result of cigarette smoking, is the leading cause of cancer death in the United States, killing over 160,000 people in 2010, more than breast, colorectal, and prostate cancer combined. Since only 10% of heavy smokers develop lung cancer and 20% of lung cancers develop in non...
What is the current status of trial NCT01982149?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2014-06. Estimated completion is 2019-05.
What interventions are being tested in trial NCT01982149?
The interventions under investigation include: Group 1 (GENETIC), Group 2 (GENETIC), Group 3 (GENETIC).
Who is sponsoring clinical trial NCT01982149?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.